Business Wire

Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Adopted by British Lighting Brand WILA for Human-Centric Lighting in Office and Educational Buildings

Share

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that WILA Lighting, specialists in personalised lighting solutions, part of The Nordeon Group, based in Oxfordshire, UK, has adopted Seoul Semiconductor’s SunLike Series natural spectrum LEDs for Visic®, WILA’s new product range.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191001005597/en/

Visic® with SunLike Series natural spectrum LEDs (Graphic: Business Wire)

Visic® with SunLike Series natural spectrum LEDs (Graphic: Business Wire)

WILA has developed Visic®, a uniquely shaped recessed ceiling luminaire, which features a human-centric lighting design closely matching the spectrum of natural sunlight. The technology lowers the blue light peak to be similar to sunlight’s spectral curve in order to reduce scattered reflection and glare common in conventional LEDs. This result is achieved with SunLike Series LEDs, an advanced lighting technology that promotes well-being by creating a more healthy and productive working environment in offices and educational buildings.

Visic® is an aesthetically attractive ceiling luminaire with its textured surfaces and soft contours. The luminaire is easy to install with a tool-less plug and play installation. Customised options are also available. The range is extremely efficient, operating up to 162 Llm/W, with a Unified Glare Rating (UGR) that achieves low glare UGR<19 rated in accordance with International Commission on Illumination (CIE) discomfort glare evaluation system. This will enable lighting designers to meet even the most challenging design requirements.

Seoul’s SunLike Series natural spectrum LEDs have been identified as a key light source for promoting human well-being, based on the results of a recent comprehensive sleep study conducted by Prof. Christian Cajochen and his team at the University of Basel in Switzerland. The paper, entitled: “Effect of Daylight LED on Visual Comfort, Melatonin, Mood, Waking Performance, and Sleep,” was published in the Journal of Lighting and Research Technology on March 24, 2019. Quoting from the paper: “We have evidence that a daylight [natural spectrum] LED solution has beneficial effects on visual comfort, daytime alertness, mood, and sleep intensity in healthy volunteers.”

Light sources with SunLike Series LEDs more accurately show the colour of objects as they would appear in natural sunlight. Optimised to natural light spectra and colour rendering of CRI-97 (close to CRI-100 of sunlight), and higher than the CRI-80 of conventional LEDs, SunLike Series LEDs deliver significant benefits in vivid colour, contrast detail, and quality of light consistency.

The SunLike Series LEDs have also achieved the highest level of eye safety certification from the International Commission on Illumination as an RG-1 level light source with no photo-biological risks.

“As the paradigm of lighting shifts to human-centric lighting, there is an increasing demand for healthy light sources for people who spend a lot of time indoors,” said Carlo Romiti, Europe sales Vice President of Seoul Semiconductor. “Beyond the function to illuminate the darkness, light sources with SunLike Series LEDs certainly bring differentiated value to the lighting industry, compared to conventional LEDs.”

Seoul Semiconductor developed SunLike Series natural spectrum LEDs in collaboration with Toshiba Materials’ TRI-R spectrum technology in 2017 as the first LED light source to closely match the spectrum of natural sunlight.

To learn more about Visic® by WILA, please visit:
https://www.wila.co.uk/news/the-shape-of-things-to-come

To learn more about the SunLike Series natural spectrum LEDs, please visit:
http://www.seoulsemicon.com/en/technology/Sunlike/

# # #

About WILA Lighting

WILA Lighting specialises in personalised lighting solutions. WILA is part of The Nordeon Group and is based in Oxfordshire, UK. WILA responds to project specific requirements with personalised lighting solutions, delivering exceptional customer service and manufacturing flexibility. Leading with innovative products and a commitment to focusing on the customer, design team and end user, WILA creates and manufactures personalised lighting products to fulfil the project design specification.

About Seoul Semiconductor

Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC. For more information, please visit www.seoulsemicon.com/en.

Contact information

Seoul Semiconductor Inc.
Jeonghee Kim
Tel: +82-70-4391-8311
Email: jeonghee.kim@seoulsemicon.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

bitFlyer Europe and Quazard Partner to Bring First Ever Trading Competition to Botwars Ultimate Trading1.6.2020 06:00:00 CESTPress release

Leading cryptocurrency exchange bitFlyer, is partnering with crypto-trading game developer Quazard, to bring the first ever gamified trading competition to the Botwars Ultimate Trading universe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200531005005/en/ bitFlyer and Quazard bring the first gamified trading competition to the Botwars Ultimate Trading universe (Graphic: Business Wire) The competition, which launches today, allows Botwars players to compete in a free to enter crypto-trading simulator to win real Bitcoin. This is the first trading competition to launch on Botwars, and the only live trading competition of its type. In Botwars Ultimate Trading, players need to build an army of trading robots (each representing a trade) and lead them into battle to conquer the cryptocurrency markets. Botwars is a real-time, gamified currency trading experience where you will learn new trading skills, unlock powerful new tradin

Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time1.6.2020 03:00:00 CESTPress release

Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19. The treatment was also able to show improvement in lung lesions to a normal activity level in animal models. The pre-clinical study was conducted in an animal model in collaboration with one of the Korean National Universities, Chungbuk National University College of Medicine. The trial set out to assess the efficacy of two dosage amounts (low and high) for the antiviral antibody treatment. In comparison to the placebo-controlled group, the research team observed improved recovery in terms of clinical symptom scores such as runny nose, cough and body aches, after the first day of treatment. From the fifth day, significant clinical remission was observed. Reverse transcriptase polymerase chain reaction (RT-PCR) measurement and cell culture-based viral diagnosis were used to a

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo